Collection description
This collection contains guidelines, forms and documents related to accessing nitisinone under the Life Saving Drugs Program. Click to view the Orfadin® product information on the Therapeutic Goods Administration website.
Guidelines
New arrangements for nitisinone (Orfadin®)
From 1 August 2026, all existing LSDP patients accessing nitisinone (Orfadin®) for the treatment of hereditary tyrosinaemia type 1 can access their medicine through the PBS. Transitional arrangements will be in place to enable existing nitisinone patients to transition to accessing their treatment through the PBS. Nitisinone (Orfadin®) will not be available through the LSDP from 1 November 2026, with no new applications being accepted from 1 August 2026.
More details about the changes to access to nitisinone is in this fact sheet: New arrangements for nitisinone (Orfadin®) – information for prescribers.
Medicines review documents
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.